Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

NACompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Gastroesophageal Reflux Disease
Interventions
OTHER

Study Arm - acid suppression plus feeding bundle

"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"

OTHER

Conventional arm - acid suppression only

-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)

Trial Locations (1)

43205

The Research Institute at Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Ohio State University

OTHER

lead

Sudarshan Jadcherla

OTHER

NCT02486263 - Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial | Biotech Hunter | Biotech Hunter